FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression

International Journal of Molecular Medicine

Volumn 34, Issue 4, 2014, Pages 1169-1174

  Ishitsuka, Asako ^a   Fujine, Etsuko ^a   Mizutani, Yoko ^a   Tawada, Chisato ^a   Kanoh, Hiroyuki ^a   Banno, Yoshiko ^a   Seishima, Mariko ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; Epidermal growth factor receptor; FTY720; Melanoma; Sphingosine 1 phosphate; Sphingosine kinase 1

Indexed keywords

CARBOPLATIN; CISPLATIN; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FINGOLIMOD; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; ANTINEOPLASTIC AGENT; LYSOPHOSPHOLIPID; PHOSPHOTRANSFERASE; PROPANEDIOL DERIVATIVE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE KINASE;

A375 CELL LINE; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; MELANOMA CELL; MELANOMA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; IC50; MELANOMA; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; INHIBITORY CONCENTRATION 50; LYSOPHOSPHOLIPIDS; MELANOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROPYLENE GLYCOLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84907468386     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1882     Document Type: Article

References (38)

1. Taha TA, Hannun, YA and Obeid LM: Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol 39: 113-131, 2006.
2. Ogretmen B and Hannun YA: Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4: 604-616, 2004. (Pubitemid 39025055)
3. Olivera A, Kohama T, Edsall LC, et al: Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J Cell Biol 147: 545-558, 1999.
4. Xia P, Wang L, Gamble JR and Vadas MA: Activation of sphingosine kinase by tumor necrosis factor-alpha inhibits apoptosis in human endothelial cells. J Biol Chem 274: 34499-34505, 1999. (Pubitemid 129511798)
5. Spiegel S and Milstien S: Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4: 397-407, 2003. (Pubitemid 36565571)
6. Xia P, Gamble JR, Wang L, et al: An oncogenic role of sphingo sine kinase. Curr Biol 10: 1527-1530, 2000. (Pubitemid 32003646)
7. Ho JW, Man K, Sun CK, Lee TK, Poon RT and Fan ST: Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol Cancer Ther 4: 1430-1438, 2005.
8. Pchejetski D, Doumerc N, Golzio M, et al: Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther 7: 1836-1845, 2008.
9. French KJ, Schrecengost RS, Lee BD, et al: Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 63: 5962-5969, 2003. (Pubitemid 37187498)
10. Shida D, Takabe K, Kapitonov D, Milstien S and Spiegel S: Targeting SphK1 as a new strategy against cancer. Curr Drug Targets 9: 662-673, 2008.
11. Vadas M, Xia P, McCaughan G and Gamble J: The role of sphingosine kinase 1 in cancer: oncogene or non-oncogene addiction? Biochim Biophys Acta 1781: 442-447, 2008.
12. Azuma H, Takahara S, Horie S, Muto S, Otsuki Y and Katsuoka Y: Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol 169: 2372-2377, 2003. (Pubitemid 36576803)
13. Ubai T, Azuma H, Kotake Y, et al: FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft. Anticancer Res 27: 75-88, 2007. (Pubitemid 46363319)
14. Billich A, Bornancin F, Dévay P, Mechtcheriakova D, Urtz N and Baumruker T: Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 278: 47408-47415, 2003. (Pubitemid 37523181)
15. Wang JD, Takahara S, Nonomura N, Ichimaru N, Toki K and Azuma H: Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate 40: 50-55, 1999. (Pubitemid 29244494)
16. Pereira FV, Arruda DC, Figueiredo CR, et al: FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system. Clinics (Sao Paulo) 68: 1018-1027, 2013.
17. LaMontagne K, Littlewood-Evans A, Schnell C, et al: Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 66: 221-231, 2006. (Pubitemid 43166028)
18. Tonelli F, Lim KG, Loveridge C, et al: FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal 22: 1536-1542, 2010.
19. Sukocheva O, Wadham C, Holmes A, et al: Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J Cell Biol 173: 301-310, 2006.
20. Shida D, Fang X, Kordula T, et al: Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res 68: 6569-6577, 2008.
21. Paugh BS, Paugh SW, Bryan L, et al: EGF regulates plas minogen activator inhibitor-1 (PAI-1) by a pathway involving c-Src, PKCdelta, and sphingosine kinase 1 in glioblastoma cells. FASEB J 22: 455-465, 2008. (Pubitemid 351225582)
22. Nemoto S, Nakamura M, Osawa Y, et al: Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation. J Biol Chem 84: 10422-10432, 2009.
23. Kawahara S, Otsuji Y, Nakamura M, et al: Sphingosine kinase 1 plays a role in the upregulation of CD44 expression through extracellular signal-regulated kinase signaling in human colon cancer cells. Anticancer Drugs 24: 473-483, 2013.
24. Guillermet-Guibert J, Davenne L, Pchejetski D, et al: Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther 8: 809-820, 2009.
25. Fuereder T, Hoeflmayer D, Jaeger-Lansky A, et al: Sphingosine kinase 1 is a relevant molecular target in gastric cancer. Anticancer Drugs 22: 245-252, 2011.
26. Pchejetski D, Bohler T, Brizuela L, et al: FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res 70: 8651-8661, 2010.
27. Heffernan-Stroud LA, Helke KL, Jenkins RW, De Costa AM, Hannun YA and Obeid LM: Defining a role for sphingosine kinase 1 in p53-dependent tumors. Oncogene 31: 1166-1175, 2012.
28. Taha TA, Osta W, Kozhaya L, et al: Down-regulation of sphin gosine kinase-1 by DNA damage: dependence on proteases and p53. J Biol Chem 279: 20546-20554, 2004. (Pubitemid 38623502)
29. Rudolf K, Cervinka M and Rudolf E: Dual inhibition of topoisomerases enhances apoptosis in melanoma cells. Neoplasma 57: 316-324, 2010.
30. Liu Y, Deng J, Wang L, et al: S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma. Blood 120: 1458-1465, 2012.
31. Dong YB, Yang HL, Elliott MJ and McMasters KM: Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors. Cancer Res 62: 1776-1783, 2002. (Pubitemid 34408502)
32. Kim D, Cheng GZ, Lindsley CW, Yang H and Cheng JQ: Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer. Curr Opin Investig Drugs 6: 1250-1258, 2005. (Pubitemid 43009206)
33. Meier F, Schittek B, Busch S, et al: The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 10: 2986-3001, 2005. (Pubitemid 40910537)
34. Sinnberg T, Lasithiotakis K, Niessner H, et al: Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol 129: 1500-1515, 2009.
35. Liu X, Powlas J, Shi Y, et al: Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth. Anticancer Res 24: 2697-2704, 2004. (Pubitemid 39407145)
36. Sun SY, Rosenberg LM, Wang X, et al: Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65: 7052-7208, 2005.
37. Francipane MG and Lagasse E: mTOR pathway in colorectal cancer: an update (Review). Oncotarget 15: 49-66, 2014
38. Rosa R, Marciano R, Malapelle U, et al: Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin Cancer Res 19: 138-147, 2013.